The Knight Medison Relationship Already Paying Dividends

MONTREAL, QUEBEC--(Marketwired - Nov. 2, 2015) - Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries ("Knight"), announced today that a dividend to Knight in the amount of NIS 5.66 million [C$1.9 million] has been approved by the Board of Directors of Medison (1995) Ltd. ("Medison") The dividend relates to Knight's 28.3% equity interest in Medison. Historically, Medison has declared dividends on a semi-annual basis.

"We are pleased with our strategic collaboration with Medison. We hope to report both financial and strategic dividends from this partnership for years to come," said Jonathan Ross Goodman, Director of Knight.

About Medison

Backed by three generations of experience in the healthcare industry since 1937, Medison is Israel's leading specialty pharmaceutical and therapeutic device company. Medison is focused on delivering innovative healthcare solutions to the Israeli and Romanian markets, including but not limited to early access programs, government registration and reimbursement, medical affairs, marketing and logistics. Medison is the exclusive Israeli partner for leading global pharma companies such as Amgen®, Biogen®, Shire® and Ipsen®. Medison also operates a fully owned subsidiary in Romania based on replicating its success in Israel, and currently represents Biogen®. For more information, please visit www.medisonpharma.com.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2014. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.